Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02079233Phase 1Completed

Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Role: lead

NCT01736735Phase 2Unknown

Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects

Role: lead

NCT01944007Phase 1Completed

Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Role: lead

NCT01598740Phase 1Completed

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

Role: lead

NCT01265524Phase 2Completed

Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

Role: lead

All 5 trials loaded